OC
CLSD

Oppenheimer & Co’s Clearside Biomedical CLSD Stock Holding History

Oppenheimer & Co’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-956
Closed -$11.5K – 1665
2025
Q2 		$11.5K Hold
956
– – ﹤0.01% 1601
2025
Q1 		$13.2K Hold
956
– – ﹤0.01% 1559
2024
Q4 		$13.6K Buy
+956
New +$15.7K ﹤0.01% 1544

Other funds holding CLSD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Oppenheimer & Co's CLSD Position: Q3 2025 in Review

Oppenheimer & Co sold out of Clearside Biomedical (CLSD) in Q3 2025, closing a stake of 956 shares — an estimated $11.5K sold.

Oppenheimer & Co first reported a position in CLSD in Q4 2024 and held it in 3 quarters. The position peaked at $13.6K in Q4 2024. 26 funds tracked by Wall St. Rank hold CLSD as of Q3 2025.

  • Oppenheimer & Co reported no remaining Clearside Biomedical position as of Q3 2025 after selling out during the quarter.
  • Oppenheimer & Co sold 956 Clearside Biomedical shares in Q3 2025, an estimated $11.5K.
  • Oppenheimer & Co first reported a position in Clearside Biomedical in Q4 2024 and held it in 3 quarters.
  • Oppenheimer & Co's Clearside Biomedical position peaked at $13.6K in Q4 2024.
  • 26 funds tracked by Wall St. Rank held Clearside Biomedical as of Q3 2025.

Based on Oppenheimer & Co's 13F filing for Q3 2025, filed 6 Nov 2025.